History of neuroprotection and rationale as a therapy for glaucoma

American Journal of Managed Care

Volumn 14, Issue SUPPL. 1, 2008, Pages

  Levin, Leonard A ^a   Peeples, Patti ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN HYDROGEN TARTRATE; MEMANTINE; PHENYTOIN; PLACEBO;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN SIZE; CELL DAMAGE; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DRUG INHIBITION; GLAUCOMA; HUMAN; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETINA GANGLION CELL; RETINA NERVE CELL; REVIEW;

DISEASE PROGRESSION; GLAUCOMA; HUMANS; MEMANTINE; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS;

EID: 40349103258     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Barkana Y, Belkin M. Neuroprotection in ophthalmology: a review. Brain Res Bull. 2004;62:447-453.
2. Levin LA. Neuroprotection and regeneration in glaucoma. Ophthalmol Clin North Am. 2005;18:585-596.
3. Neuroprotection: Drugs, Markets and Companies. Biotechnology Management Reports. January 2007. http://www.bioportfolio.com/cgi-bin/acatalog/ Neuroprotection_Drugs_Markets_and_Companies.html. Accessed May 14, 2007.
4. Belkin M. Neuroprotection: A great promise yet to be fulfilled. Glaucoma Today. 2007;5. www.glaucomatoday.com/pages/current/04.html. Accessed May 11, 2007.
5. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischaemic stroke. N Engl J Med. 2006;354:588-600.
6. Allergan reports fourth quarter operating results [press release]. Irvine, CA: Allergan, Inc; January 31, 2007. www.shareholder.com/agn/ ReleaseDetail.cfm?ReleaseID=227679. Accessed May 11, 2007.
7. Hill MD. Stroke: the dashed hopes of neuroprotection. Lancet Neurol. 2007;6:2-3.
8. Levin LA. Neurobiologic Rationale for Neuroprotection. Chapter 1. In: Glaucoma Neuroprotection Monograph. Weinreb RW, ed. Philadelphia, PA: Wolters Kluwer Health; 2006.
9. Ritch R. Complementary therapy for the treatment of glaucoma: a perspective. Ophthalmol Clin North Am. 2005;18:597-609.
10. Greenfield DS. Measuring Neuroprotection in Glaucoma Clinical Trials. Chapter 8. In: Glaucoma Neuroprotection Monograph. Weinreb RW, ed. Philadelphia, PA: Wolters Kluwer Health; 2006.
11. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;24:CD001447.
12. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585-591.
13. Cosman KM, Boyle LL, Porsteinsson AP. Memantine in the treatment of mild-to-moderate Alzheimer's disease. Expert Opin Pharmacother. 2007;8:203-214.
14. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
15. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405-1411.
16. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA. 1997;277:1597-1604.
17. Levin LA. Extrapolation of animal models of optic nerve injury to clinical trial design. J Glaucoma. 2004;13:1-5.
18. Coleman WP, Benzel D, Cahill DW, et al. A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord. 2000;13:185-199.
19. The AGIS Investigators. The advanced glaucoma intervention study, 6: effect of cataract on visual field and visual acuity. The AGIS Investigators. Arch Ophthalmol. 2000;118:1639-1652.
20. Advanced Glaucoma Intervention Study Investigators. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials. 1994;15:299-325.
21. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498-505.
22. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487-497.
23. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomised to medications or surgery. Ophthalmology. 2001;108:1943-1953.
24. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
25. American Academy of Ophthalmology, Glaucoma Panel. Primary open-angle glaucoma preferred practice pattern. San Francisco, CA: American Academy of Ophthalmology; 2000:1-36.
26. Becker B, Stamper RL, Asseff C, Podos SM. Effect of diphenylhydantoin on glaucomatous field loss: a preliminary report. Trans Am Acad Ophthalmol Otolaryngol. 1972;76:412-422.
27. Bakalash S, Shlomo GB, Aloni E, et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J Mol Med. 2005;83:904-916.